Overview We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more comp...
Q2 FY2026 — expected 2026-08-20
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | STTK | discussed_in_filing Artificial Intelligence | |
| topic_mention | STTK | discussed_in_filing Cybersecurity | |
| topic_mention | STTK | discussed_in_filing Trusted Computing | |
| topic_mention | STTK | discussed_in_filing Blockchain & Crypto | |
| topic_mention | STTK | discussed_in_filing Autonomous Vehicles | |
| topic_mention | STTK | discussed_in_filing Regulation | |
| topic_mention | STTK | discussed_in_filing Automotive | |
| topic_mention | STTK | discussed_in_filing Healthcare & Bio | |
| topic_mention | STTK | discussed_in_filing Platform & Ecosystem | |
| topic_mention | STTK | discussed_in_filing Sovereign & Government | |
| topic_mention | STTK | discussed_in_filing Artificial Intelligence | |
| topic_mention | STTK | discussed_in_filing Cybersecurity | |
| topic_mention | STTK | discussed_in_filing Trusted Computing | |
| topic_mention | STTK | discussed_in_filing Blockchain & Crypto | |
| topic_mention | STTK | discussed_in_filing Autonomous Vehicles | |
| topic_mention | STTK | discussed_in_filing Regulation | |
| topic_mention | STTK | discussed_in_filing Automotive | |
| topic_mention | STTK | discussed_in_filing Healthcare & Bio | |
| topic_mention | STTK | discussed_in_filing Platform & Ecosystem | |
| topic_mention | STTK | discussed_in_filing Sovereign & Government |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001628280-26-014989 | EDGAR | 67K words |
| 2025-03-27 | 2024-12-31 | 0001680367-25-000012 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001680367-24-000014 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001680367-23-000019 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001680367-22-000005 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001680367-21-000008 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001680367-25-000057 | EDGAR | 22K words |
| 2025-08-14 | 2025-06-30 | 0001680367-25-000046 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001680367-25-000034 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001680367-24-000053 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001680367-24-000040 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001680367-24-000025 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001680367-23-000062 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001680367-23-000050 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001680367-23-000035 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001680367-22-000034 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001680367-22-000020 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001680367-22-000015 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001628280-26-014987 | EDGAR | 3K words |
| 2026-02-05 | 0001193125-26-039488 | EDGAR | — |
| 2026-01-22 | 0001193125-26-019682 | EDGAR | — |
| 2025-11-06 | 0001680367-25-000056 | EDGAR | — |
| 2025-08-26 | 0001193125-25-188078 | EDGAR | — |
| 2025-08-14 | 0001680367-25-000044 | EDGAR | — |
| 2025-08-05 | 0001193125-25-173010 | EDGAR | — |
| 2025-07-15 | 0001193125-25-159387 | EDGAR | — |
| 2025-05-01 | 0001680367-25-000030 | EDGAR | — |
| 2025-03-27 | 0001680367-25-000009 | EDGAR | — |
86 total filings indexed. 58 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001680367 |
| Ticker | STTK |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report